Update on Therapeutic Drug Monitoring in Crohn's Disease

被引：11
|
作者：
Heron, Valerie [1 ]
Afif, Waqqas [1 ]
机构：
[1] McGill Univ, Montreal Gen Hosp, Hlth Ctr, Div Gastroenterol, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada
来源：
GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2017年 / 46卷 / 03期
关键词：
Therapeutic drug monitoring; Biologics; Anti-tumor necrosis factor; Drug concentrations; Anti-drug antibodies; Crohn's disease; Inflammatory bowel disease; INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB TROUGH LEVELS; ADALIMUMAB DRUG; ANTIBODY CONCENTRATIONS; ANTIDRUG ANTIBODIES; MAINTENANCE THERAPY; CLINICAL-RESPONSE; RANDOMIZED-TRIAL; DOSE-ESCALATION; REMISSION;
D O I：
10.1016/j.gtc.2017.05.014
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In patients with Crohn's disease on biologic medications, the use of therapeutic drug monitoring leads to a personalized approach to optimize treatment. Using an algorithmic approach, measurement of drug concentrations and anti-drug antibodies can be used to improve treatment outcomes. Therapeutic drug concentrations and absence of antibodies are associated with improved clinical and endoscopic outcomes. In clinical practice, therapeutic drug monitoring has been shown to be clinically useful and cost-effective in patients experiencing a loss of response to treatment. This review highlights the available data on therapeutic drug monitoring in the treatment of patients with Crohn's disease on biologic medications.
引用
收藏
页码：645 / +
页数：16
相关论文
共 50 条
  • [1] Therapeutic drug monitoring in Crohn's disease
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (03): : 150 - 150
  • [2] Therapeutic Drug Monitoring of Biologics in Crohn?s Disease
    Grossberg, Laurie B.
    Cheifetz, Adam S.
    Papamichael, Konstantinos
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2022, 51 (02) : 299 - 317
  • [3] Therapeutic Drug Monitoring in Perianal Fistulizing Crohn's Disease
    Zulqarnain, Mir
    Deepak, Parakkal
    Yarur, Andres J.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
  • [4] Therapeutic drug monitoring of methotrexate in patients with Crohn's disease
    van de Meeberg, Maartje M.
    Fidder, Herma H.
    Oldenburg, Bas
    Sundaresan, Janani
    Struys, Eduard A.
    Montazeri, Nahid S. M.
    Mares, Wout G. N.
    Mahmmod, Nofel
    van Asseldonk, Dirk P.
    Lutgens, Maurice W. M. D.
    Kuyvenhoven, Johan P.
    Rietdijk, Svend T.
    Nissen, Loes H. C.
    Koehestanie, Parweez
    de Boer, Nanne K. H.
    de Jonge, Robert
    Bouma, Gerd
    Calasan, Maja Bulatovic
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (11-12) : 1151 - 1162
  • [5] Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease
    Papamichael, Konstantinos
    Dubinsky, Marla C.
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2023, 164 (01) : 164 - 165
  • [6] Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease
    Wright, Emily K.
    Kamm, Michael A.
    De Cruz, Peter
    Hamilton, Amy L.
    Selvaraj, Fabiyola
    Princen, Fred
    Gorelik, Alexandra
    Liew, Danny
    Prideaux, Lani
    Lawrance, Ian C.
    Andrews, Jane M.
    Bampton, Peter A.
    Jakobovits, Simon L.
    Florin, Timothy H.
    Gibson, Peter R.
    Debinski, Henry
    Macrae, Finlay A.
    Samuel, Douglas
    Kronborg, Ian
    Radford-Smith, Graham
    Gearry, Richard B.
    Selby, Warwick
    Bell, Sally J.
    Brown, Steven J.
    Connell, William R.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (06): : 653 - 661
  • [7] Key insights from therapeutic drug monitoring in Crohn's disease patients
    Seinen, Margien L.
    De Boer, Nanne K.
    van Bodegraven, Adriaan A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (05) : 399 - 406
  • [8] USTEKINUMAB THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS WITH LOSS OF RESPONSE
    Heron, Valerie
    Bessissow, Talat
    Bitton, Alain
    Lakatos, Peter L.
    Seidman, Ernest G.
    Jain, Anjali
    Battat, Robert
    Germain, Pascale
    Lemieux, Carolyne
    Afif, Waqqas
    GASTROENTEROLOGY, 2019, 156 (06) : S1139 - S1139
  • [9] Improved Remission with Proactive Therapeutic Drug Monitoring of Ustekinumab for Crohn's Disease
    Shahab, Omer
    Sterling, Richard
    Gaidos, Jill
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S453 - S453
  • [10] USTEKINUMAB THERAPEUTIC DRUG MONITORING IN PEDIATRIC CROHN'S DISEASE AND ULCERATIVE COLITIS
    Appel, Keren
    Ziring, David
    Gonzales, Yvette
    Arora, Yogesh
    Du, Lillian
    Mcgovern, Dermot P. B.
    Rabizadeh, Shervin
    GASTROENTEROLOGY, 2021, 160 (06) : S724 - S725
12345